The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Is erlotinib for first-line use in EGFR+ non-small-cell lung cancer cost-effective?
David L Veenstra
Consultant or Advisory Role - Genentech
Preeti S. Bajaj
Consultant or Advisory Role - Genentech
Josh John Carlson
Consultant or Advisory Role - Genentech
Hans-Peter Goertz
Employment or Leadership Position - Genentech/Roche
Stock Ownership - Roche